Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer
Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer Initiation of Phase 1 study in biochemically recurrent prostate cancer anticipated in Q2 April 05, 2021 08:00 ET | Source: Advaxis, Inc. Advaxis, Inc. Princeton, New Jersey, UNITED STATES PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, toda...